Search Within

Connie Wing-Ching Lee Batlevi

Formats
  1. Meeting Abstract (110)
  2. Journal Article (52)
  3. Research Letter (5)
  4. Book Section (4)
  5. Miscellaneous (2)
  6. Review (2)
  7. Correspondence (1)
  8. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (177)
  2. Department of Medicine (177)
  3. Hematologic Malignancies, Division of (177)
  4. Lymphoma (177)
  5. Survivorship Research (118)
  6. Epidemiology and Biostatistics (90)

More Groups

People
  1. Maria Palomba (99)
  2. Anas Younes (81)
  3. Andrew Zelenetz (77)
  4. Matthew Matasar (71)
  5. Ariela Noy (61)
  6. David Straus (61)

More People

Years
  1. 2024 (3)
  2. 2023 (11)
  3. 2022 (30)
  4. 2021 (27)
  5. 2020 (27)
  6. 2019 (34)

More Years

Publications
  1. Blood (70)
  2. Hematological Oncology (16)
  3. Blood Advances (12)
  4. Journal of Clinical Oncology (10)
  5. Blood Cancer Journal (6)
  6. Biology of Blood and Marrow Transplantation (5)

More Publications

Publishers
  1. American Society of Hematology (83)
  2. Wiley Blackwell (16)
  3. Elsevier Inc. (15)
  4. Nature Publishing Group (15)
  5. American Society of Clinical Oncology (10)
  6. John Wiley & Sons (4)

More Publishers

Results (177)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • TP53 mutations and RNA binding protein MUSASHI 2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
    Meeting Abstract

    Erazo, I. T.; Evans, C. M.; Zakheim, D.; Chu, K. L.; Barbash, O.; Refermat, A. Y.; Batlevi, C. L.; Younes, A.; Kharas, M. G.
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Molecular and genetic characterization of tumor samples from patients with relapsed or refractory follicular lymphoma identifies factors influencing response to tazemetostat
    Meeting Abstract

    Dave, S. S.; Happ, L.; Yasso, C.; Salles, G.; Batlevi, C. L.; Phillips, T.; Yang, J.; Adib, D.; Michaud, N. R.; Morschhauser, F.
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim analysis of the randomized phase 1b/3 study evaluating the safety and efficacy of tazemetostat plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Park, S. I.; Nastoupil, L.; Phillips, T.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Pagel, J. M.; Leonard, J. P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Successful incorporation of electronic patient-reported outcomes using PROMIS-29 into standard of care for lymphoma patients receiving CD19-directed chimeric antigen receptor T (CAR T) cell therapy
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Sauter, C.; Batlevi, C.; Dahi, P. B.; Lin, R.; Palomba, M. L.; Perales, M. A.; Giralt, S. A.
    Quality of Life Research (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Updates in therapies of relapsed and refractory follicular lymphoma [Interview]
    Miscellaneous

    Batlevi, C. L.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save